A University of Alberta study shows that rural Albertans living with multiple sclerosis are not as likely as urban patients ...

Biostate AI and the Accelerated Cure Project will to develop AI models to predict multiple sclerosis progression and ...

Ageing is associated with significant immunological changes that can influence both the progression of the disease and the ...

MS patients in the U.S. with Medicaid coverage have worse disease outcomes compared with those who have private insurance, a ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis. Results from the HERCULES phase 3 study showed delay in disability ...

To build a model that used routine clinical information to screen for anxiety and depression, Patten's group studied 828 MS ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...